Inflammation and macular oedema after pars plana vitrectomy
- PMID: 24288446
- PMCID: PMC3833009
- DOI: 10.1155/2013/971758
Inflammation and macular oedema after pars plana vitrectomy
Abstract
Cystoid macular oedema (CMO) is a major cause of reduced vision following intraocular surgery. Although the aetiology of CMO is not completely clarified, intraocular inflammation is known to play a major role in its development. The macula may develop cytotoxic oedema when the primary lesion and fluid accumulation occur in the parenchymatous cells (intracellular oedema) or vasogenic oedema when the primary defect occurs in the blood-retinal barrier and leads to extracellular fluid accumulation (extracellular oedema). We report on the mechanisms of CMO formation after pars plana vitrectomy and associated surgical procedures and discuss possible therapeutic approaches.
References
-
- Colin J. The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs. 2007;67(9):1291–1308. - PubMed
-
- Loewenstein A, Zur D. Postsurgical cystoid macular edema. Developments in Ophthalmology. 2010;47:148–159. - PubMed
-
- Sivaprasad S, Bunce C, Patel N. Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews. 2005;(1)CD004239 - PubMed
-
- Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE. Macular edema. Survey of Ophthalmology. 2004;49(5):470–490. - PubMed
-
- Scholl S, Kirchhof J, Augustin AJ. Pathophysiology of macular edema. Ophthalmologica. 2010;224(supplement 1):8–15. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
